Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
about
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenThe impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.Developments in the therapeutic applications of bisphosphonates.The pharmacology of bisphosphonates and new insights into their mechanisms of action.Changing perceptions in osteoporosis. Several risk factors are important.Bisphosphonates in osteoporosis: recent clinical experience.Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis.Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fracturesThe gastrointestinal tolerability and safety of oral bisphosphonates.Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis.Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities.Long-term experience with alendronate in the treatment of osteoporosis.Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal womenTheoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.Effects of antiresorptive treatment on nonvertebral fracture outcomes.Suppression of alveolar bone resorption by etidronate treatment for periodontal disease: 4- to 5-year follow-up of four patients.Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.Seven years of treatment with risedronate in women with postmenopausal osteoporosis.
P2860
Q24242665-2C8708D1-CE75-4D0C-BC44-23FD76071604Q33268786-3DAD33B6-0745-440F-B901-FFC1ED4DBD53Q33678028-731C1986-7D7B-4D4B-A2A0-32A8D9CF7A1CQ33746152-51B85063-0918-4D32-9CE0-746F9DF10F1FQ33798835-DE9E45DA-7258-4350-8FD4-3614B77ED22DQ34182230-71E74020-48B4-4142-986C-F4DCFFF34FFEQ35050241-4E8B4A25-DEEB-4ADE-9CE0-DAEE2A4FEA30Q35147978-86472EA5-F49E-4121-A864-01D4ABCAD3FDQ35194544-2910FE03-A4E1-4A35-90F3-A63245481897Q35194552-EFF93CDA-F26A-4377-A8B0-9FADD3134925Q35593989-C2301766-F568-48E9-8296-18AB80B32A5BQ35775369-4EBA4CD0-95EE-4AFA-9FB9-B39CCD06B1C7Q36491814-6E3CBF98-7F34-40CD-9D61-5BAE04F2406AQ37018947-99AD4F11-D898-4953-B0B2-9AF6B8E9CD1BQ37305028-DB839554-6823-4406-B3A3-8651C6E30BE7Q44488735-2DE9AA98-2E00-4F52-8C58-1634BE84CFBFQ44715973-751DAE70-3268-48DD-A9C3-FD3293669BD3Q44961465-1B718090-57CA-4A36-9067-DBADF5BAC3DCQ45083822-03E5A05E-E4C3-46B6-BE80-B9B9724F596F
P2860
Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Cyclical etidronate in the tre ...... fter seven years of treatment.
@en
Cyclical etidronate in the tre ...... fter seven years of treatment.
@nl
type
label
Cyclical etidronate in the tre ...... fter seven years of treatment.
@en
Cyclical etidronate in the tre ...... fter seven years of treatment.
@nl
prefLabel
Cyclical etidronate in the tre ...... fter seven years of treatment.
@en
Cyclical etidronate in the tre ...... fter seven years of treatment.
@nl
P2093
P1476
Cyclical etidronate in the tre ...... fter seven years of treatment.
@en
P2093
Chesnut CH 3rd
Hoseyni MS
Jackson RD
Schoenfeld SL
P304
P356
10.1016/S0002-9343(97)00278-7
P407
P577
1997-12-01T00:00:00Z